COVID-19 Aftereffects (Long COVID) Associated with Wuhan, Delta, and Omicron Variants Reported in Japanese Hospitals



Abstract Views
268

Downloads
220

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Feb 13, 2023
Published Apr 30, 2024
10.24018/ejmed.2024.6.2.1686

Abstract viewed = 268 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

COVID-19 patients who visited hospitals in Japan reported aftereffects, also known as Long COVID or Post COVID symptoms. The studycompared the Long COVID symptoms caused by the original Wuhan, Delta, and Omicron variants. The analysis of COVID-19 lingering symptoms(Post COVID) conducted by researchers in Japan have been included. Symptoms may last from one month to one year, putting a strain on thehealth care system. According to a joint study done by Osaka University and Toyonaka City on patients mostly infected with Omicron, one in fivepatients experienced aftereffects one month after their recovery.

The report indicated that the symptoms improved over time. A majority of the patients reported difficulties with their daily activities. About 14%of the patients experienced aftereffects even one year after being discharged from hospitals, according to data recorded during Delta and previous waves that were presented to the Japanese government. Patients hospitalized during the Delta and Wuhan waves for SARS-CoV-2 infection showed a 50% reduction in symptoms between three and six months, according to a longitudinal follow-up study of sequelae. According to a gender-wise study, symptoms improved more quickly in women than in men. Compared to older patients, younger patients recovered a little faster in the firsttwo months. Patients infected during the first four non-Delta waves recovered slower than those infected during the Omicron surge. Longitudinalstudies of persistent symptoms are needed to develop treatments and possibly the COVID-19-specific drugs.

Keywords: Aftereffects Long COVID Wuhan strain Omicron variant Delta variant SARS-CoV-2 mutation

Downloads

Download data is not yet available.

References

  1. Nippon.com. Japanese Studies Find Long-Term Effects of COVID-19. [Internet] 2021 [cited 2021 July 5] Available from: https://www.nippon.com/en/japan-data/h01053/.
     Google Scholar
  2. Otsuka Y, Tokumasu K, Nakano Y, Honda H, Sakurada Y, Sunada N, et al. Clinical characteristics of Japanese patients who visited a COVID-19 aftercare clinic for post-acute sequelae of COVID-19/long COVID. Cureus. 2021; 13(10).
    DOI  |   Google Scholar
  3. Sunada N, Honda H, Nakano Y, Yamamoto K, Tokumasu K, Sakurada Y, et al. Hormonal trends in patients suffering from long COVID symptoms. Endocrine Journal. 2022; 69(10): 1173-1181.
    DOI  |   Google Scholar
  4. The Mainichi. 60% of recovering COVID-19 patients in Japan claimed loss of smell, taste: health ministry. [Internet] 2021 [cited 2021 June 18] Available from: https://mainichi.jp/english/articles/20210617/p2a/00m/0li/028000c.
     Google Scholar
  5. The Mainichi. COVID aftereffects more common in women, possibly linked to immune system: Japan researcher. [Internet] 2021 [2022 July 24] Availabel from: https://mainichi.jp/english/articles/20220720/p2a/00m/0sc/024000c.
     Google Scholar
  6. Shervani Z, Khan I, Siddiqui NY, Khan T, Qazi UY. Risk of SARS-CoV-2 Transmission from Humans to Pets and Vice Versa. European Journal of Medical and Health Sciences. 2021; 3(1): 34-38.
    DOI  |   Google Scholar
  7. Shervani Z, Khan I, Khan T, Qazi UY. World’s fastest supercomputer picks COVID-19 drug. Advances in Infectious Diseases. 2020; 10(3): 211-225.
    DOI  |   Google Scholar
  8. Shervani Z, Khan I, Qazi UY. COVID-19 vaccine. Advances in Infectious Diseases. 2020; 10(3): 195-210.
    DOI  |   Google Scholar
  9. Shervani Z, Khan I, Qazi UY. SARS-CoV-2 delayed Tokyo 2020 Olympics: Very recent advances in covid-19 detection, treatment, and vaccine development useful conducting the games in 2021. Advances in Infectious Diseases. 2020; 10(3): 56-66.
    DOI  |   Google Scholar
  10. Shervani Z, Qazi UY, Khan MJ, Fatma K, Siddiquie A, Vuyyuru VP, et al. COVID-19 in Karnataka: Rise of Omicron. European Journal of Medical and Health Sciences. 2022; 4(6): 71-76.
    DOI  |   Google Scholar
  11. Shervani Z, Jamal N, Qazi UY, Hasan S, Fatma K, Siddiquie A, et al. Prevalence and Pathogenicity of Omicron Varian. European Journal of Medical and Health Sciences. 2022; 4(5): 125-32.
    DOI  |   Google Scholar
  12. Shervani Z, Bhardwaj D, Sherwani A, Khan I, Qazi UY. COVID-19 infection in 8 big cities of India: The Dynamics of the Spread and Seropositivity. European Journal of Medical and Health Sciences. 2021; 3(6): 1-5.
    DOI  |   Google Scholar
  13. Shervani Z, Bhardwaj D, Nikhat R. COVID-19 infection in India: Seropositivity versus the Dynamics of the Spread. European Journal of Medical and Health Sciences. 2021; 3(4): 95-99.
    DOI  |   Google Scholar
  14. Shervani Z, Bhardwaj D, Nikhat R. Ibbrahim A, Hasan S, Khan I, et al. Serosurvey of Haryana and Odisha: COVID-19 Hybrid Immunity. European Journal of Medical and Health Sciences. 2022; 4(2): 27-32.
    DOI  |   Google Scholar
  15. Shervani Z, Bhardwaj D, Nikhat R. Ibbrahim A, Khan I, Qazi UY, et al. 4th National Sero Survey of India: Vaccine Generated Antibodies Enhancement. European Journal of Medical and Health Sciences. 2022; 4(1): 27-32.
    DOI  |   Google Scholar
  16. Shervani Z, Bhardwaj D, Nikhat R. Ibbrahim A, Khan I, Hasan S, et al. 5th and 6th Sero Survey of Delhi: Vaccine Activated Antibodies Enhancement. European Journal of Medical and Health Sciences. 2022; 4(1): 61-66.
    DOI  |   Google Scholar
  17. Shervani Z. COVID-19 in Kerala: Health Index Theory. European Journal of Medical and Health Sciences. 2021; 3(2): 21-24.
    DOI  |   Google Scholar
  18. Shervani Z. COVID-19 in Kerala: The Dynamics of Spread and Health Index Theory. RAS Medical Science. 2021; 1(2): 1-3.
    DOI  |   Google Scholar
  19. Shervani Z, Bhardwaj D, Nikhat R. Dharavi Slums (Mumbai, India): The Petri Dish of COVID-19 Herd Immunity. European Journal of Medical and Health Sciences. 2021; 3(3): 38-41.
    DOI  |   Google Scholar
  20. Shervani Z, Khan I, Siddiqui NY, Khan T, Qazi UY. Viability of SARS-CoV-2 and Sanitization Methods. European Journal of Medical and Health Sciences. 2021; 3(1): 22-27.
    DOI  |   Google Scholar
  21. Shervani Z, Fatma K, Hasan S, Siddiquie A, Vuyyuru VP, Jamal N, et al. Mild Nature of SARS-CoV-2 Breakthrough Infections in Healthcare Workers in India. European Journal of Medical and Health Sciences. 2022; 4(4): 26-33.
    DOI  |   Google Scholar
  22. Shervani Z, Nikhat R, Hasan S, Qazi UY, Fatma K, Siddiquie A, et al. COVID-19 in India: Breakthrough Infections in Delta Wave. European Journal of Medical and Health Sciences. 2022; 4(4): 12-16.
    DOI  |   Google Scholar
  23. Shervani Z, Bhardwaj D, Purang M, Ibbrahim A, Vuyyuru VP, Hasan S, et al. The Omicron Variant: Prevalence, Transmissibility, and Pathogenicity. European Journal of Medical and Health Sciences. 2022; 4(3): 84-91.
    DOI  |   Google Scholar
  24. Thiruvengadam R, Rizvi ZA, Raghavan S, Murugesan DR, Gosain M, Dandotiya J, et al. Clinical and experimental evidence suggest omicron variant of SARS-CoV-2 is inherently less pathogenic than delta variant independent of previous immunity. European Journal of Medical Research.2023; 28:421.
    DOI  |   Google Scholar
  25. Shervani Z, Bhardwaj D, Hasan S, Qazi UY, Purang M, Ibbrahim A, et al. The Omicron Wave in India, Mumbai, and Delhi: Prevalence and Pathogenicity. European Journal of Medical and Health Sciences. 2022; 4(3): 123-130.
    DOI  |   Google Scholar
  26. The Japan Times. Survey finds over 5% face COVID-19 aftereffects for one month. [Internet] 2022 [2022 December 19] Available from: https://www.japantimes.co.jp/news/2022/12/19/national/science-health/covid-aftereffects/.
     Google Scholar
  27. The Asahi Shimbun. Survey: 5% of COVID patients have after-effects one month later. [Internet] 2022 [2022 December 15] Available from: https://www.asahi.com/ajw/articles/14793278.
     Google Scholar
  28. News on Japan. Survey: About 5% of COVID patients have aftereffects one month after onset. [Internet] 2022 [2022 December 5] Available from: https://www.newsonjapan.com/html/newsdesk/article/136297.php.
     Google Scholar
  29. The Asahi Shimbun. Study: 13.6% of COVID-19 patients suffer long-term effects. [Internet] 2022 [2022 June 2] Available from: https://www.asahi.com/ajw/articles/14635827.
     Google Scholar
  30. The Japan Time. Some 10% suffer COVID-19 aftereffects one year after discharge: survey. [Internet] 2022 [2022 May 8]. Available from: https://www.japantimes.co.jp/news/2022/05/08/national/science-health/covid-19-aftereffects/.
     Google Scholar
  31. Sakurada Y, Sunada N, Honda H, Tokumasu K, Otsuka Y, Nakano Y, et al. Serial changes of long COVID symptoms and clinical utility of serum antibody titers for evaluation of long COVID. Journal of Clinical Medicine. 2022; 11(5): 1309.
    DOI  |   Google Scholar


Most read articles by the same author(s)

1 2 > >>